Trends in Formulation October 2025 eBook

Non-parenteral alternatives for biologics remain a clinical imperative and a formidable challenge.

Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.

A growing demand for liquid medicines is driven by patient groups' unique needs, improving compliance through flexible and palatable dosing options.